Earnings summaries and quarterly performance for APTARGROUP.
Executive leadership at APTARGROUP.
Stephan B. Tanda
Detailed
President and Chief Executive Officer
CEO
GT
Gael Touya
Detailed
President of Aptar Pharma
HT
Hedi Tlili
Detailed
President of Aptar Closures
KY
Kimberly Y. Chainey
Detailed
Executive Vice President, Chief Legal Officer and Secretary
MP
Marc Prieur
Detailed
President of Aptar Beauty
VK
Vanessa Kanu
Detailed
Executive Vice President and Chief Financial Officer
XG
Xiangwei Gong
Detailed
Executive Vice President, Strategic Group Development and President of Aptar Asia
Board of directors at APTARGROUP.
BC
B. Craig Owens
Detailed
Director
CM
Candace Matthews
Detailed
Chair of the Board
GL
George L. Fotiades
Detailed
Director
GK
Giovanna Kampouri Monnas
Detailed
Director
IM
Isabel Marey-Semper
Detailed
Director
JX
Julie Xing
Detailed
Director
MT
Matt Trerotola
Detailed
Director
RK
Ralf K. Wunderlich
Detailed
Director
SG
Sarah Glickman
Detailed
Director
Research analysts who have asked questions during APTARGROUP earnings calls.
DR
Daniel Rizzo
Jefferies
4 questions for ATR
Also covers: APD, ASH, AZZ +16 more
Gabe Hajde
Wells Fargo & Company
4 questions for ATR
Also covers: AMBP, AMCR, BALL +12 more
GS
George Staphos
Bank of America
4 questions for ATR
Also covers: AMBP, AMCR, AVY +18 more
Ghansham Panjabi
Robert W. Baird & Co.
4 questions for ATR
Also covers: AMCR, AVNT, AVY +20 more
ML
Matthew Larew
William Blair & Company
3 questions for ATR
Also covers: AMED, DNA, MASS +10 more
Matthew Roberts
Raymond James
3 questions for ATR
Also covers: AMCR, AVY, GEF +4 more
Recent press releases and 8-K filings for ATR.
AptarGroup Announces Q4 and Full-Year 2025 Results
ATR
Earnings
Guidance Update
Debt Issuance
- AptarGroup reported strong Q4 2025 sales growth of 14% to $963 million, with core sales up 5%, and full-year 2025 reported sales increasing 5% to $3.8 billion.
- Adjusted EPS for Q4 2025 was $1.25, down from $1.62 in the prior year, while full-year adjusted EPS was $5.74, a slight decline of 1%. Adjusted EBITDA margin for Q4 was 19.8%, impacted by product mix and higher production costs in beauty and closures.
- The Pharma segment's core sales grew 4% (or 10% excluding emergency medicine), driven by strong demand in systemic nasal drug delivery and 24% growth in injectables. Beauty core sales increased 10%, and Closures core sales increased 1%.
- For 2026, the company anticipates continued strong growth in Pharma (excluding emergency medicine), improving demand in Beauty, and steady performance in Closures, while expecting a $65 million year-over-year headwind from emergency medicine.
- AptarGroup returned $486 million to shareholders in 2025 through share repurchases and dividends and issued $600 million of 4.75% senior notes in Q4 2025.
6 hours ago
AptarGroup Announces Q4 and Full-Year 2025 Results
ATR
Earnings
Guidance Update
Dividends
- AptarGroup reported Q4 2025 reported sales of $963 million, a 14% increase, and full-year 2025 reported sales of $3.8 billion, up 5%.
- Q4 2025 adjusted EBITDA margin was approximately 20% and adjusted EPS was $1.25, impacted by higher production costs in beauty enclosures and a decline in emergency medicine demand.
- All three segments delivered core sales growth in Q4 2025, with pharma core sales up 4% (10% excluding emergency medicine), beauty core sales up 10%, and closures core sales up 1%.
- The company returned $486 million to shareholders in 2025, marking its 32nd consecutive year of increasing dividends, and anticipates sequential quarterly improvements in beauty and closures margins through the first half of 2026, with a stronger second half for full-year margins.
7 hours ago
AptarGroup Reports Q4 and Full-Year 2025 Results, Provides Q1 2026 Outlook
ATR
Earnings
Guidance Update
Share Buyback
- AptarGroup reported Q4 2025 core sales growth of 5% and a 14% increase in reported sales, contributing to full-year 2025 core sales growth of 2%.
- Q4 2025 adjusted EBITDA decreased 2% to $191 million, with adjusted EPS at $1.25, primarily due to product mix, higher production costs in beauty, and declining emergency medicine demand.
- The company expects Q1 2026 adjusted EPS to be between $1.13-$1.21 per share and anticipates a $65 million revenue headwind from emergency medicine in 2026, mainly in the first half.
- A new share repurchase authorization of up to $600 million was announced, following $365 million in share repurchases for the full year 2025.
- The Pharma segment saw 4% core sales growth in Q4 2025, with injectables increasing 24% and prescription sales (excluding emergency medicines) growing 10%.
8 hours ago
AptarGroup Reports Strong Q4 and Full Year 2025 Results, Announces New Share Repurchase Authorization
ATR
Earnings
Share Buyback
Dividends
- AptarGroup reported strong Q4 2025 performance with 14% reported sales growth and 5% core sales growth, achieving $1.25 adjusted earnings per share. For the full year 2025, reported sales grew 5% and core sales grew 2%, with adjusted earnings per share of $5.74 and adjusted EBITDA reaching $815 million.
- The company returned $206 million to shareholders in Q4 2025 and $486 million for the full year 2025 through share repurchases and dividends. The Board also approved a new authorization for the repurchase of up to $600 million of common stock , marking the 32nd consecutive year of paying an annually increasing dividend.
- Free cash flow for FY 2025 was $303 million. The company provided an outlook for Q1 2026, projecting adjusted net income attributable to AptarGroup, Inc. per diluted share between $1.13 and $1.21.
1 day ago
Aptar Reports Fourth Quarter and Annual 2025 Results
ATR
Earnings
Share Buyback
Guidance Update
- AptarGroup reported fourth quarter 2025 reported sales increased 14% and core sales increased 5%, with reported earnings per share decreasing 24% to $1.13. For the full year 2025, reported sales increased 5% and reported earnings per share increased 7% to $5.89.
- The company returned $206 million to shareholders in Q4 2025 and $486 million for the full year 2025 through share repurchases and dividends. A new authorization for the repurchase of up to $600 million of common stock was approved.
- AptarGroup provided first quarter 2026 adjusted earnings per share guidance in the range of $1.13 to $1.21.
- All three segments delivered core sales growth in Q4 2025, but product mix and higher production costs reduced overall profitability for the quarter.
1 day ago
Aptar Highlights Pharma Growth, Injectables Expansion, and Narcan Headwinds at JPMorgan Conference
ATR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Aptar's Pharma business is the primary growth and profit engine, representing 46% of the company and two-thirds of its EBITDA, with its pipeline's average weighted value increasing 54% since 2019.
- The company has significantly invested in its Injectables business, bringing new capacity online in 2025 across the US, China, and Europe, to capitalize on the exploding GLP-1 market.
- Aptar anticipates a $65 million year-over-year headwind in Narcan sales, expected primarily in the first half of 2026, following a 50% growth in the first half of 2025 and subsequent inventory normalization.
- Aptar maintains a balanced capital allocation strategy, investing 70% in business growth and returning 30% to shareholders, including a 32-year streak of rising dividends and significant share repurchases in 2025.
Jan 14, 2026, 4:15 PM
Aptar Highlights Strong Pharma Segment Performance and Strategic Growth Initiatives
ATR
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- Aptar's Pharma segment reported Net Sales of $1.6B and Adjusted EBITDA of $568M for FY 2024, with Net Sales of $1.3B and Adjusted EBITDA of $465M for the first nine months of 2025.
- The company has returned over $1B to shareholders through dividends and share repurchases since 2020, while reinvesting approximately 70% of capital into core business operations and growth initiatives.
- Proprietary Drug Delivery Systems accounted for 72% of Pharma Segment Sales in FY 2024 , with injectables showing over 50% revenue growth from 2022-2024 and GLP-1 revenue growing more than 40% in the first nine months of 2025 compared to FY 2024.
- Aptar is expanding its digital health offerings, supporting over 4 million users across 120+ countries, and has a robust pipeline of new technologies, including ActivShield™ and Activ-Blister™.
Jan 14, 2026, 4:15 PM
Aptar Provides Business Update at JPMorgan Healthcare Conference
ATR
Guidance Update
Share Buyback
Dividends
- Aptar's Pharma business is the largest segment, contributing 46% of revenue and two-thirds of EBITDA, with a top-line growth guidance of 7-11% and 32-36% EBITDA margin.
- The company's Pharma pipeline has significantly increased since 2019, with a 54% rise in average weighted value and a 46% increase in opportunities, driven by systemic nasal drug delivery, nose-to-brain applications, and injectables, particularly for GLP-1s.
- Aptar anticipates a $65 million year-over-year headwind in the first half of 2026 due to a "reset" in Narcan sales following inventory build-up, though long-term growth for the medication is still expected.
- The capital allocation strategy involves approximately 70% investment in business growth (organic and inorganic) and 30% return to shareholders, including 32 years of rising dividends and opportunistic share buybacks, with $270 million remaining in authorization at the end of Q3, expected to be fully utilized in Q4 and Q1.
- The Beauty and Closures businesses have undergone significant renovation and are now in "good fighting shape," showing positive growth signals.
Jan 14, 2026, 4:15 PM
Aptar Highlights Pharma Growth Drivers, Pipeline, and Capital Allocation at JPMorgan Healthcare Conference
ATR
Guidance Update
New Projects/Investments
Share Buyback
- Aptar's Pharma business is the company's largest segment, contributing 46% of the company and two-thirds of EBITDA, driven by proprietary drug delivery systems and a growing pipeline. The overall Pharma market is growing at 7%.
- The company's Pharma pipeline has seen substantial growth, with the average weighted value increasing 54% and the number of opportunities rising 46% since 2019, focusing on systemic nasal drug delivery, biologics for injectables, and new propellants.
- Aptar's injectables business is experiencing an "exploding" market, particularly with GLP-1s, and has made significant investments in capacity across Europe, the U.S. (Congers, New York), and China to meet demand.
- Capital allocation prioritizes investing 70% into business growth (organic and inorganic) and 30% to shareholders, including 32 years of rising dividends and opportunistic share buybacks. The company expects to fully utilize $270 million in share buyback authorization in Q4 (previous year) and Q1 (current year).
- Narcan sales are undergoing a reset following 50% growth in the first half of 2025, leading to an expected $65 million year-over-year headwind largely in the first half of 2026 due to channel inventory build-up.
Jan 14, 2026, 4:15 PM
Aptar's Nasal System Delivers First FDA-Approved PSVT Treatment
ATR
Product Launch
New Projects/Investments
- Aptar's Bidose Liquid Nasal Spray System is the delivery mechanism for CARDAMYST™ (etripamil), the first and only self-administered FDA-approved nasal spray for paroxysmal supraventricular tachycardia (PSVT) in adults.
- Developed by Milestone Pharmaceuticals, CARDAMYST received U.S. Food and Drug Administration (FDA) approval for converting acute symptomatic episodes of PSVT to sinus rhythm.
- This approval broadens Aptar’s drug delivery solutions into new therapeutic areas and underscores the increasing demand for nasal drug delivery.
- An estimated two million people in the United States are diagnosed with PSVT, indicating a significant market for this new treatment.
Dec 17, 2025, 10:00 PM
Quarterly earnings call transcripts for APTARGROUP.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more